ATYR Deadline: ATYR Investors with Losses in Excess of $100K Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].